Literature DB >> 22419128

SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence.

Faranaz Atschekzei1, Jörg Hennenlotter, Stefanie Jänisch, Annika Großhennig, Wolfgang Tränkenschuh, Sandra Waalkes, Inga Peters, Thilo Dörk, Axel S Merseburger, Arnulf Stenzl, Markus A Kuczyk, Jürgen Serth.   

Abstract

Loss of the secreted Fzd-related protein 1 (SFRP1) and concurrent alteration of the SFRP1/WNT pathway are frequently observed in human cancers such as in renal cell cancer (RCC). Whether methylation of a SFRP1 CpG island locus in normal human solid tissues is associated with increased tissue specific cancer risk has not been determined to date. Here we measure the cancer risk attributable to SFRP1 DNA methylation in renal tissue. Pyrosequencing of bisulfite treated DNA was used for a case-control study including 120 normal-appearing renal tissues of autopsy specimens and 72 normal-appearing tissues obtained from tumor adjacent areas, and a cross sectional study of 96 RCCs. Association of methylation with demographic risk factor age, clinicopathological parameters and course of patients was investigated. We show significant hypermethylation of a SFRP1 CpG island locus in normal-appearing renal tissues from RCC patients compared with normal-appearing autopsy kidney tissues. Inter quartile analysis revealed a 6-, 13- and 11-fold increased cancer risk for the second, third and fourth quartiles of methylation in the age matched subgroup of tissues (p = 0.001, p = 1.3E-6, p = 6.9E-6). Methylation in autopsy tissues increased with age and methylation in tumors was an independent predictor of recurrence free survival. SFRP1 DNA methylation, accumulates with age in normal-appearing kidney tissues and is associated with increased renal cancer risk, suggesting this CGI sub region as an epigenetic susceptibility locus for RCC. Our data underline the need to further analyze the tissue specific risks conferred by methylated loci for the development of human cancers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22419128     DOI: 10.4161/epi.19614

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  17 in total

1.  Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.

Authors:  Julia Mendoza-Pérez; Jian Gu; Luis A Herrera; Nizar M Tannir; Shanyu Zhang; Surena Matin; Jose A Karam; Christopher G Wood; Xifeng Wu
Journal:  Cancer       Date:  2017-05-23       Impact factor: 6.860

2.  Identification of DNA methylation patterns and biomarkers for clear-cell renal cell carcinoma by multi-omics data analysis.

Authors:  Pengfei Liu; Weidong Tian
Journal:  PeerJ       Date:  2020-08-03       Impact factor: 2.984

Review 3.  The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments.

Authors:  Javier C Angulo; Claudia Manini; Jose I López; Angel Pueyo; Begoña Colás; Santiago Ropero
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

4.  Age-, tumor-, and metastatic tissue-associated DNA hypermethylation of a T-box brain 1 locus in human kidney tissue.

Authors:  Jürgen Serth; Inga Peters; Natalia Dubrowinskaja; Christel Reese; Knut Albrecht; Michael Klintschar; Marcel Lafos; Alexander Grote; Albert Becker; Jörg Hennenlotter; Arnulf Stenzl; Hossein Tezval; Markus A Kuczyk
Journal:  Clin Epigenetics       Date:  2020-02-18       Impact factor: 6.551

5.  Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma.

Authors:  K Gebauer; I Peters; N Dubrowinskaja; J Hennenlotter; M Abbas; R Scherer; H Tezval; A S Merseburger; A Stenzl; M A Kuczyk; J Serth
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

6.  Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response.

Authors:  Natalia Dubrowinskaja; Kai Gebauer; Inga Peters; Jörg Hennenlotter; Mahmoud Abbas; Ralph Scherer; Hossein Tezval; Axel S Merseburger; Arnulf Stenzl; Viktor Grünwald; Markus A Kuczyk; Jürgen Serth
Journal:  Cancer Med       Date:  2014-01-27       Impact factor: 4.452

7.  GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma.

Authors:  Inga Peters; Kai Gebauer; Natalia Dubrowinskaja; Faranaz Atschekzei; Mario W Kramer; Joerg Hennenlotter; Hossein Tezval; Mahmoud Abbas; Ralph Scherer; Axel S Merseburger; Arnulf Stenzl; Markus A Kuczyk; Juergen Serth
Journal:  Oncol Rep       Date:  2014-02-18       Impact factor: 3.906

8.  Bioinformatics-based identification of miR-542-5p as a predictive biomarker in breast cancer therapy.

Authors:  Qiong-Ni Zhu; Helen Renaud; Ying Guo
Journal:  Hereditas       Date:  2018-01-15       Impact factor: 3.271

9.  Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.

Authors:  Ivonne Regel; Melanie Eichenmüller; Ujjwal Mukund Mahajan; Beate Hagl; Simone Benitz; Beate Häberle; Christian Vokuhl; Dietrich von Schweinitz; Roland Kappler
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-18       Impact factor: 4.553

10.  Weighted Gene Coexpression Network Analysis to Construct Competitive Endogenous RNA Network in Chromogenic Renal Cell Carcinoma.

Authors:  Yong-Bo Chen; Liang Gao; Jin-Dong Zhang; Jiang Guo; Ping-Hong You; Liang-You Tang; Ying-Wen Liu
Journal:  Biomed Res Int       Date:  2021-06-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.